MX2018006030A - Inmunoensayo para la determinacion de anticuerpos modificados en la region de fragmento cristalizable (fc). - Google Patents

Inmunoensayo para la determinacion de anticuerpos modificados en la region de fragmento cristalizable (fc).

Info

Publication number
MX2018006030A
MX2018006030A MX2018006030A MX2018006030A MX2018006030A MX 2018006030 A MX2018006030 A MX 2018006030A MX 2018006030 A MX2018006030 A MX 2018006030A MX 2018006030 A MX2018006030 A MX 2018006030A MX 2018006030 A MX2018006030 A MX 2018006030A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
immobilized
determination
amount
Prior art date
Application number
MX2018006030A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018006030A publication Critical patent/MX2018006030A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con un método para la determinación de la cantidad de un anticuerpo bivalente en una muestra de suero o plasma obtenida de un animal de experimentación no humano, en donde el anticuerpo comprende una o más mutaciones en la región Fc en comparación con la región Fc de tipo salvaje correspondiente que tiene una secuencia de SEC ID NO: 01, 02 ? 03, en donde el método comprende las siguientes etapas: a) inmovilizar un polipéptido no anticuerpo al que se conjuga covalentemente más de una copia del antígeno del anticuerpo en una superficie sólida, b) incubar el antígeno inmovilizado con la muestra para formar un complejo antígeno-anticuerpo inmovilizado, c) incubar el complejo antígeno-anticuerpo inmovilizado con el antígeno conjugado con una etiqueta detectable para formar un complejo ternario inmovilizado, y d) determinar la cantidad de anticuerpo determinando la cantidad de la etiqueta detectable en el complejo ternario inmovilizado.
MX2018006030A 2015-11-30 2016-11-29 Inmunoensayo para la determinacion de anticuerpos modificados en la region de fragmento cristalizable (fc). MX2018006030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15197058 2015-11-30
PCT/EP2016/079086 WO2017093226A1 (en) 2015-11-30 2016-11-29 Immunoassay for the determination of fc-region modified antibodies

Publications (1)

Publication Number Publication Date
MX2018006030A true MX2018006030A (es) 2018-08-01

Family

ID=54770889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006030A MX2018006030A (es) 2015-11-30 2016-11-29 Inmunoensayo para la determinacion de anticuerpos modificados en la region de fragmento cristalizable (fc).

Country Status (12)

Country Link
US (1) US11561229B2 (es)
EP (1) EP3384293B1 (es)
JP (1) JP6807944B2 (es)
KR (1) KR102628570B1 (es)
CN (2) CN108351361A (es)
AU (1) AU2016363638B2 (es)
BR (1) BR112018008789A2 (es)
CA (1) CA3004199C (es)
HK (1) HK1258302A1 (es)
IL (1) IL259053A (es)
MX (1) MX2018006030A (es)
WO (1) WO2017093226A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPH01223351A (ja) * 1988-03-03 1989-09-06 Dainippon Pharmaceut Co Ltd 抗体の定量方法および定量用試薬
IL92164A (en) 1988-11-03 1996-01-19 Igen Inc Particle-based electrochemiluminescent test method
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Luminescence test method and device based on magnetic tiny particles, containing many magnets
AU4698096A (en) * 1995-01-18 1996-08-07 First Medical, Inc. Method for immobilizing haptens on a test article
US20040242848A1 (en) * 2003-04-21 2004-12-02 Owens S. Michael Mouse/human chimeric anti-phencyclidine antibody and uses thereof
US7658930B2 (en) 2005-02-02 2010-02-09 Peng Cui Kit for detecting the antibody of HCV and its preparing method
RU2296332C1 (ru) 2005-10-28 2007-03-27 Общество с ограниченной ответственностью "ДИАМЕДИКА" Способ ранней диагностики факта потребления наркотических веществ в отсутствие клинических признаков состояния зависимости от наркотиков
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN104428006B (zh) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
CN104471397B (zh) * 2012-07-13 2018-03-23 弗·哈夫曼-拉罗切有限公司 用于检测多特异性结合物的方法
RU2694981C2 (ru) * 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения

Also Published As

Publication number Publication date
KR102628570B1 (ko) 2024-01-23
WO2017093226A1 (en) 2017-06-08
AU2016363638A1 (en) 2018-05-24
CA3004199C (en) 2024-05-07
KR20180082597A (ko) 2018-07-18
BR112018008789A2 (pt) 2018-10-30
JP2018536881A (ja) 2018-12-13
CA3004199A1 (en) 2017-06-08
AU2016363638B2 (en) 2022-04-21
CN108351361A (zh) 2018-07-31
JP6807944B2 (ja) 2021-01-06
HK1258302A1 (zh) 2019-11-08
US11561229B2 (en) 2023-01-24
US20180364251A1 (en) 2018-12-20
EP3384293B1 (en) 2020-07-08
IL259053A (en) 2018-07-31
EP3384293A1 (en) 2018-10-10
CN118150838A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
Li et al. A nanobody-based electrochemiluminescent immunosensor for sensitive detection of human procalcitonin
HRP20200482T1 (hr) Dijagnostičke analize i setovi za detekciju folat receptora 1
HRP20160461T1 (hr) Solubilna humana st-2 antitijela i eseji
JP2018042573A5 (es)
WO2012007903A3 (en) A method of detecting surrogate markers for active tuberculosis in a serum sample
BR112015022844A2 (pt) métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes
JP2016512044A5 (es)
JP2011507810A5 (es)
MX2015012824A (es) Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
JP2010536043A5 (es)
JP2015535344A5 (es)
JP2011521216A5 (es)
JP2019015737A5 (es)
JP2010539161A5 (es)
JP2019015736A5 (es)
HRP20230217T1 (hr) Rep protein kao proteinski antigen za upotrebu u dijagnostičkim testovima
Sotnikov et al. Mathematical modeling of bioassays
JP2022043219A (ja) 糖ペプチドと反応するモノクローナル抗体およびその用途
HRP20220770T1 (hr) Sintetske kontrole za imunohistokemiju
Ayoglu et al. Bead arrays for antibody and complement profiling reveal joint contribution of antibody isotypes to C3 deposition
MX2018006030A (es) Inmunoensayo para la determinacion de anticuerpos modificados en la region de fragmento cristalizable (fc).
MX2017005156A (es) Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.
JPWO2014157723A1 (ja) インスリン測定方法
EP4253950A3 (en) Ce-western applications for antibody development
WO2021217140A3 (en) Specificity enhancing reagents for covid-19 antibody testing